Local News: Amalia, NM 

 | 

Sign Up

 | 

Sign In

Advertisment

Novartis Wire

Comprehensive News Feed for Novartis.

Results 1 - 20 of 575 in Novartis

  1. EU raids pharmaceutical companies for anticompetitive business dealsRead the original story

    Yesterday | Domain-B

    ... Laboratories Ltd, India's biggest drug maker, Sanofi-Aventis SA, Teva Pharmaceutical Industries and a unit of Novartis AG as part of a widened probe of settlements between drug makers and brand-name pharmaceutical companies. (See: EU official raid ...

    Comment?

  2. A Strategy for All SituationsRead the original story

    Wednesday | The Motley Fool

    ... desired price or lower by your option's expiration, or to be paid income if not. If you think, for example, that Novartis (NYSE: NVS ) is a good business at a good price, then writing puts on the stock is a sensible strategy, one that will could pay ...

    Comment?

    Related Topix: Financial Markets, Telecom, Computers, Cisco Systems

  3. Welcome to Club Biogeneric, Pfizer

    Wednesday | The Motley Fool

    ... the club of drugmakers developing generic versions of biologic drugs, according to Bloomberg. (Nasdaq: TEVA ) , Novartis (NYSE: NVS ) , Hospira , and a few others have already gained approval in Europe for copycat versions of drugs such as Amgen 's ...

    Comment?

    Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Teva Pharmaceutical Industries, Johnson and Johnson, Amgen

  4. Wednesday's biggest gaining and declining stocksRead the original story

    Wednesday | MarketWatch

    Among the companies whose shares are expected to see active trade in Wednesday's session are Apple, Men's Wearhouse, Novartis, PepsiCo, Powell, Sara Lee, and TI.

    Comment?

    Related Topix: Financial Markets, Beverages, PepsiCo, Biotech, Powell Industries, Electronics

  5. Novartis AG Talks Up Promising Cancer PortfolioRead the original story

    Wednesday | BioSpace

    Novartis AG expects to file for two new approvals of cancer drugs, including big hope Tasigna, by the end of the month and has several more on the way to further boost its lucrative portfolio.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  6. Novartis highlights cancer drugs at R&D dayRead the original story

    Wednesday | MarketWatch

    Swiss drugmaker Novartis on Wednesday said it's looking to build out its portfolio with 16 new compounds, with a particular focus on cancer drugs.

    Comment?

    Related Topix: Biotech, Medicine, Cancer

  7. ASA404 to feature in Novartis Oncology Pipeline Update and at San Antonio Breast Cancer SymposiumRead the original story

    Wednesday | Market Wire

    LONDON and CAMBRIDGE, MA and BASEL, SWITZERLAND-- - Antisoma plc announces that Novartis, its partner for ASA404, will feature ASA404 in today's Oncology pipeline update for investors.

    Comment?

    Related Topix: Biotech, Medicine, Health, Breast Cancer, Healthcare Industry, Oncology, Cambridge, MA, Lung Cancer

  8. Mike Peed: Bark Hot Dogs, in North Park Slope.Read the original story

    Tuesday Dec 8 | New Yorker

    ... GRAPH: HONORE BROWN James Surowiecki speaks with Dan Vasella, the chairman and C.E.O. of the pharmaceutical company Novartis AG. MOCA , in L.A. MOMA .

    Comment?

    Related Topix: Dining

  9. Europeans Inspect Fewer Than 19 Chinese Drug Factories a YearRead the original story

    Tuesday Dec 8 | BNET

    ... 19 times in 2008, even though Western drug companies such as Pfizer (PFE), AstraZeneca (AZN), Eli Lilly (LLY) and Novartis (NVS) have hundreds of sites in China. (Source: EMEA. Click To enlarge.) BNET reported last week that the U.S. FDA has just ...

    Comment?

    Related Topix: Pfizer, Biotech, Medicine, AstraZeneca Group, Healthcare Industry, Eli Lilly

  10. Rankin to get new trialRead the original story

    May 2, 2005 | Leader Post

    ... in 2000 for $521-million, and Cobequid Life Sciences Inc., which was bought in that same year for $21-million by Novartis AG. Mr. Rankin was cleared of more serious insider-trading charges. However, he appealed his tipping conviction. "With the ...

    Comment?

  11. Novartis's Tasigna Beats Gleevec in Leukemia Study; May Be `Blockbuster'Read the original story

    Tuesday Dec 8 | Bloomberg.com

    Novartis AG a s Tasigna, which ranks outside the Swiss drugmakera s top 20 products after two years on the market, may turn into a $1 billion seller after tests showed it was better at treating newly diagnosed leukemia than Gleevec.

    Comment?

    Related Topix: Biotech, Leukemia, Health, Medicine, Healthcare Industry, Oncology

  12. Ariad, Cephalon Make ASH Splash: BioBuzzRead the original story

    Tuesday Dec 8 | TheStreet.com

    ... acute lymphoblastic leukemia (Ph+ CLL.) These are hard-to-treat patients because current leukemia drugs, including Novartis' ( NVS Quote ) Gleevec and Tasigna and Bristol-Myers Squibb's ( BMY Quote ) Sprycel, have limited or no positive effect. ...

    Comment?

    Related Topix: Biotech, Cephalon, Medicine, Healthcare Industry, Leukemia, Health, ARIAD Pharmaceuticals, Bristol Myers Squibb, Lymphoma

  13. Better Drug Stock: Pfizer or Merck?Read the original story

    Tuesday Dec 8 | The Motley Fool

    ... Each of these five rankings need more context -- like, how these companies stack up against key competitors such as Novartis (NYSE: NVS ) and Bristol-Myers Squibb (NYSE: BMY ) . But these basic numbers suggest that Merck is a better buy. What do you ...

    Comment?

    Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Pfizer

  14. U.S. FDA Panel Backs Novartis AG Transplant DrugRead the original story

    Tuesday Dec 8 | BioSpace

    A U.S. advisory panel recommended approval of a Novartis AG drug to prevent rejection of transplanted kidneys, a Food and Drug Administration spokeswoman said on Monday.

    Comment?

    Related Topix: Biotech, Food and Drug Administration, Medicine, Healthcare Industry

  15. Skepticism on Swine Flu's Danger Limits Europe's Pandemic Vaccine Demand

    Tuesday Dec 8 | Bloomberg.com

    ... against the pandemic virus by early next year. Public concerns that the vaccines made by GlaxoSmithKline Plc , Novartis AG and Baxter International Inc. may cause serious side effects have kept some Europeans on the sidelines since governments began ...

    Comment?

    Related Topix: Epidemic, Natural Disasters, Biotech, Medicine, Healthcare Industry, Baxter International, Medical Equipment, Deerfield, IL

  16. Are You Playing With Fire?Read the original story

    Tuesday Dec 8 | The Motley Fool

    ... loved." I was messing with small biotechs. Names you'd never hear until one Monday morning they were snapped up by Novartis (NYSE: NVS ) or Bristol-Meyers Squibb (NYSE: BMY ) . And tiny exploration and production outfits that summarily popped on ...

    Comment?

  17. Talking Business: Dan VasellaRead the original story

    Monday Dec 7 | New Yorker

    James Surowiecki speaks with Dan Vasella, the chairman and C.E.O. of the pharmaceutical company Novartis AG, about the current state of the industry, the company's shift away from the traditional model of profitability, and the growing influence of countries such as China, where Novartis plans to open a billion-dollar facility.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  18. Table of Contents: December 14, 2009 : The New YorkerRead the original story w/Photo

    Monday Dec 7 | New Yorker

    ... of Lydia Davis." James Surowiecki speaks with Dan Vasella, the chairman and C.E.O. of the pharmaceutical company Novartis AG. Browse the complete archive using the cover gallery. DVD of the Week : Richard Brody on "Women of the Night." Red Red Wine ...

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  19. MDB Capital i-banker lands at Idera Pharma

    Monday Dec 7 | Tech Confidential Blog

    ... pivotal time for Idera. The Massachusetts biotech announced recently that it was terminating a key partnership with Novartis AG (NYSE:NVS). The companies had for four years collaborated on the respiratory disease compound IMO-2134, with Novartis ...

    Comment?

    Related Topix: Biotech, Idera Pharmaceuticals, Merck , Healthcare Industry

  20. InCyte's Experimental Pre-Leukemia Drug Curbed Symptoms, Research Finds

    Saturday Dec 5 | Bloomberg Business News

    ... patients with a disorder linked to acute leukemia, a study found. The drug, licensed last month by Swiss drugmaker Novartis A.G. , shrank spleen size, limited fatigue and improved walking ability in the research, reported today at the American ...

    Comment?

    Related Topix: Biotech, Medicine, Incyte, Healthcare Industry, Leukemia, Health, Texas